Volume 18, Number 9—September 2012
CME ACTIVITY - Policy Review
Control of Fluoroquinolone Resistance through Successful Regulation, Australia
Table 2
Drug (date registered) | Indication |
---|---|
Difloxacin (2001) | Treatment of infections in dogs caused by difloxacin-sensitive organisms |
Enrofloxacin (2004) | Treatment of urinary and respiratory tract infections, deep pyodermas, wounds, abscesses, and discharging sinuses in dogs caused by enrofloxacin-susceptible bacteria |
Orbifloxacin (1999) | Treatment of diseases in dogs and cats caused by orbifloxacin-sensitive bacteria |
Ibafloxacin (2007) | Treatment of urinary tract, respiratory tract, skin, and soft tissue infections in dogs and cats caused by ibafloxacin-sensitive bacteria |
Page created: August 17, 2012
Page updated: August 17, 2012
Page reviewed: August 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.